LLY vs. MTD: Eli Lilly vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do Eli Lilly (LLY) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but LLY is classified in Pharmaceuticals while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Profile Item	LLY	MTD
Name	Eli Lilly and Company	Mettler-Toledo International Inc.
Country/Region	United States	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	1,206.07 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	June 1, 1972	November 14, 1997
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

LLY

MTD

GSPC

Eli Lilly (LLY) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Eli Lilly (LLY) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Eli Lilly (LLY) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
Total Return (1Y)	52.36%	21.58%
Total Return (3Y, Annualized)	34.18%	19.54%
Total Return (5Y, Annualized)	41.08%	2.36%

Risk Profile

Drawdown History

LLY

MTD

GSPC

Eli Lilly (LLY) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Eli Lilly (LLY) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
Volatility (1Y, Annualized)	35.34%	31.70%
Beta (5Y)	0.40	1.15
Max Drawdown (5Y)	-34.48%	-43.47%
Avg. Volume (3M)	2.52M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

LLY and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
Sharpe Ratio (1Y)	1.36	0.55
Sortino Ratio (1Y)	2.29	0.75

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Eli Lilly (LLY) earns 86.02% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max: 109.18%
LLY: 86.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both Eli Lilly (LLY) at 31.90% and Mettler-Toledo (MTD) at 22.25% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY: 31.90%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Eli Lilly (LLY) at 53.66% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max: 83.12%
LLY: 53.66%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
ROE (TTM)	86.02%	--
ROA (TTM)	21.06%	20.09%
Net Margin (TTM)	31.90%	22.25%
Operating Margin (TTM)	53.66%	28.70%
Gross Margin (TTM)	83.63%	59.16%

Growth

Revenue Growth

Both Eli Lilly (LLY) at 44.70% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Mettler-Toledo (MTD) at 3.88% is closer to the peer norm — faster per-share earnings growth for LLY.

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
Revenue Growth (YoY)	44.70%	3.98%
Revenue Growth (3Y CAGR)	31.69%	0.90%
EPS Growth (YoY)	95.99%	3.88%
EPS Growth (3Y CAGR)	51.71%	3.06%

Financial Strength

Current Ratio (MRQ)

Both Eli Lilly (LLY) at 1.39 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
LLY: 1.39
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but MTD is more stretched: Eli Lilly (LLY) at 1.23 sits in the higher-leverage quartile and Mettler-Toledo (MTD) at 26.06 is above its industry benchmark range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max: 1.42
LLY: 1.23
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
Current Ratio (MRQ)	1.39	1.10
Debt / Equity (MRQ)	1.23	26.06
Net Debt / EBITDA	0.96	1.58

Dividends

Dividend Yield (TTM)

Mettler-Toledo (MTD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY: 0.49%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Mettler-Toledo (MTD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY: 21.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
Dividend Yield (TTM)	0.49%	0.00%
Dividend Payout Ratio (TTM)	21.71%	0.00%

Valuation

P/E Ratio (TTM)

Mettler-Toledo (MTD) at 37.38 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max: 85.34
LLY: 43.95
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Eli Lilly (LLY) at 13.95 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max: 58.18
Q3: 25.77
LLY: 13.95
Median: 7.30
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Eli Lilly (LLY) at 29.96 and Mettler-Toledo (MTD) at 442.71 look expensive — each P/B ratio sits above its industry’s benchmark range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY: 29.96
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Eli Lilly (LLY) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and Mettler-Toledo (MTD)
Metric	LLY	MTD
P/E Ratio (TTM)	43.95	37.38
P/S Ratio (TTM)	13.95	8.16
P/B Ratio (MRQ)	29.96	442.71
Free Cash Flow Yield (TTM)	0.77%	1.97%